T
ALXN

TOBAM’s Alexion Pharmaceuticals ALXN Stock Holding History

TOBAM’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-718
Closed -$112K – 449
2020
Q4 		$112K Hold
718
– – 0.01% 238
2020
Q3 		$82K Buy
+718
New +$77.5K ﹤0.01% 243
2018
Q2 		– Sell
-117,676
Closed -$13.1M – 175
2018
Q1 		$13.1M Sell
117,676
-216,282
-65% -$25.9M 0.54% 65
2017
Q4 		$39.9M Sell
333,958
-32,892
-9% -$4.01M 1.73% 14
2017
Q3 		$51.5M Sell
366,850
-53,965
-13% -$7.33M 1.94% 10
2017
Q2 		$51.2M Buy
420,815
+147,028
+54% +$17.1M 1.91% 14
2017
Q1 		$33.2M Buy
273,787
+199,294
+268% +$25.7M 1.28% 32
2016
Q4 		$9.11M Buy
74,493
+59,692
+403% +$7.3M 0.37% 64
2016
Q3 		$1.81M Buy
+14,801
New +$1.91M 0.07% 101

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TOBAM's ALXN Position: Q1 2021 in Review

TOBAM sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 718 shares — an estimated $112K sold.

TOBAM first reported a position in ALXN in Q3 2016 and held it in 9 quarters. The position peaked at $51.5M in Q3 2017. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • TOBAM reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • TOBAM sold 718 Alexion Pharmaceuticals shares in Q1 2021, an estimated $112K.
  • TOBAM first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 9 quarters.
  • TOBAM's Alexion Pharmaceuticals position peaked at $51.5M in Q3 2017.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on TOBAM's 13F filing for Q1 2021, filed 11 May 2021.